Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Oct 27, 2014; 6(10): 738-744
Published online Oct 27, 2014. doi: 10.4254/wjh.v6.i10.738
Published online Oct 27, 2014. doi: 10.4254/wjh.v6.i10.738
Lipid-lowering agents in the management of nonalcoholic fatty liver disease
Konstantinos Tziomalos, First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, 54636 Thessaloniki, Greece
Author contributions: Tziomalos K solely contributed to this manuscript.
Correspondence to: Konstantinos Tziomalos, MD, PhD, First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Kiriakidi 1, 54636 Thessaloniki, Greece. ktziomalos@yahoo.com
Telephone: +30-2310-994621 Fax: +30-2310-994773
Received: May 18, 2014
Revised: August 22, 2014
Accepted: September 6, 2014
Published online: October 27, 2014
Revised: August 22, 2014
Accepted: September 6, 2014
Published online: October 27, 2014
Core Tip
Core tip: Accumulating data suggest that statins are safe in patients with nonalcoholic fatty liver disease (NAFLD) and that they reduce the increased cardiovascular morbidity of this population. However, it is still unclear whether statins are also useful as a treatment for NAFLD per se, since there are very limited and conflicting data on their effects on liver histology. There is also very scarce evidence regarding the safety and efficacy of other lipid-lowering agents in patients with NAFLD.